Browsing by Issue Date, starting with "2025-09"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- Metabolism-Targeted Therapy in NSCLC - A New Theranostics Inhalation Approach Using Lactate Functionalized and Selenium-Chrysin Loaded Nanoparticles (SeChry@PURE-LA).Publication . Mendes, Cindy; Martins, Filipa; Granja, Sara; Gonçalves, Joana; Barros, Hélio; Casimiro, Teresa; Aguiar-Ricardo, Ana; Silva, Fernanda; Abreu, Bruna; Cristovão, Miguel; André, Saudade; Pereira, Sofia A; Baltazar, Fátima; Cabral-Marques, Helena; Gaspar, Maria Manuela; Gonçalves, Luís G; Bonifácio, Vasco D B; Serpa, JacintaLung cancer is one of the most lethal cancers globally, primarily due to delayed diagnosis and lack of specific and effective therapy. Increased lactate production and consumption, along with cysteine metabolic reliance, are features identified in NSCLC in our recent studies. Cancer metabolic remodeling leads to excessive ROS production, triggering oxidative stress, promoting angiogenesis, causing cellular and tissue damage, and contributing to various pathophysiological changes. This study aimed to investigate the therapeutic potential of selenium-chrysin (SeChry), a cysteine metabolism inhibitor, and its delivery targeted at MCT1 by encapsulation in fourth-generation polyurea dendrimers functionalized with lactic acid (PURE-LA), the nanoformulation SeChry@PURE-LA, in NSCLC. We explored the impact of SeChry nanoformulation on cell death mechanisms, including ferroptosis, and its influence on angiogenesis in in vitro and in vivo models. SeChry@PURE-LA induces cell death through the induction of intracellular ROS and lipid peroxides, resulting in distinct expression patterns of ferroptosis-associated genes across cell lines. Experiments using chicken embryo chorioallantoic membrane (CAM) and mouse orthotopic xenograft models revealed a trend toward decreased tumor growth and angiogenesis with SeChry@PURE-LA administration. These findings suggest the potential of SeChry@PURE-LA as an innovative therapeutic approach for NSCLC, highlighting its impact on cell death mechanisms and anti-angiogenic effects.
- Impact of Anatomical Resection on Non-transplantable Recurrence Among Patients with Hepatocellular Carcinoma: An International Multicenter Inverse Probability of Treatment Weighting Analysis.Publication . Kawashima, Jun; Endo, Yutaka; Khalil, Mujtaba; Woldesenbet, Selamawit; Akabane, Miho; Ruzzenente, Andrea; Ratti, Francesca; Marques, Hugo; Oliveira, Sara; Balaia, Jorge; Cauchy, François; Lam, Vincent; Poultsides, George; Kitago, Minoru; Popescu, Irinel; Martel, Guillaume; Gleisner, Ana; Hugh, Thomas J; Aldrighetti, Luca; Endo, Itaru; Pawlik, Timothy MBackground: Among patients with hepatocellular carcinoma (HCC), the impact of anatomic resection (AR) versus non-anatomic resection (NAR) on non-transplantable recurrence (NTR) remains poorly defined. We sought to compare the risk of NTR among patients treated with AR versus NAR as the primary surgical strategy for HCC. Patients and methods: Patients with HCC within Milan criteria who underwent curative-intent resection between 2000 and 2020 were identified from an international multi-institutional database. The inverse probability of treatment weighting (IPTW) method was utilized to compare short- and long-term outcomes among patients undergoing AR versus NAR. Results: Among 1038 patients, 747 (72.0%) patients underwent AR, while 291 (28.0%) patients underwent NAR. After IPTW adjustment, patients who underwent AR had better 5-year recurrence-free survival than individuals treated with NAR (63.9 vs. 52.0%; hazard ratio [HR] 0.78; 95% confidence interval [CI] 0.62-0.99); however, there was no difference in 5-year overall survival (80.2 vs. 75.6%; HR 0.76; 95% CI 0.55-1.05). Notably, individuals who underwent AR were less likely to have a NTR versus individuals treated with NAR (3-year NTR 9.8 vs. 14.4%; HR 0.62; 95% CI 0.40-0.96). In particular, AR was associated with a lower risk of NTR among patients with a medium tumor burden score (TBS) (HR 0.53; 95% CI 0.28-0.99), while the benefit among patients with a low TBS was less pronounced (HR 0.73; 95% CI 0.40-1.32). Conclusions: AR was associated with a lower risk of NTR and improved recurrence-free survival (RFS) among patients with HCC, especially individuals with higher TBS. An anatomically defined surgical approach should be strongly considered in patients with a higher HCC tumor burden.
- Recomendações sobre Contraceção em Mulheres com Cancro Ginecológico: Do Diagnóstico ao Pós-Tratamento.Publication . Correia, Lúcia; Teves, Mariana; Pires, Mónica; Pacheco, Amália; Palma, FátimaA incidência de cancro ginecológico em mulheres durante a idade fértil está a aumentar, suscitando uma preocupação crescente com a preservação da fertilidade. Nesse contexto, torna-se essencial oferecer aconselhamento contracetivo adequado a estas doentes. Na escolha do método contracetivo, é fundamental considerar o tipo histológico do tumor e a sua expressão de recetores hormonais, bem como o momento em que o aconselhamento está a ser prestado no cuidado da doente oncológica, seja na fase de diagnóstico, de tratamento ou após o tratamento oncológico. A Sociedade Portuguesa da Contraceção e a Secção de Ginecologia Oncológica da Sociedade Portuguesa de Ginecologia apresentam recomendações sobre contraceção nas mulheres com diagnóstico de cancro ginecológico submetidas a tratamentos preservadores da fertilidade, desde o diagnóstico até ao término da idade fértil